Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Pediatrics, Perinatology and Child Health
Reference88 articles.
1. Advanced Accelerator Applications (2016) NETSPOT prescribing information. Initial U.S. approval 2016. https://s3-eu-west-1.amazonaws.com/s3-adacap-product/wp-content/uploads/2020/01/02132418/nda208547-pi-20191011.pdf. Accessed 18 Dec 2019
2. Virgolini I, Ambrosini V, Bomanji J et al (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004–2010
3. Advanced Accelerator Applications (2018) LUTATHERA prescribing information. Initial U.S. approval 2018. https://s3-eu-west-1.amazonaws.com/s3-adacap-product/wp-content/uploads/2018/11/30140531/LUTATHERA_lutetium_Lu_177_dotatate_FDA_Prescribing_Information1.pdf. Accessed 18 Dec 2019
4. Zaknun J, Bodei L, Mueller-Brand J et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 40:800–816
5. Alexander N, Vali R, Ahmadzadehfar H et al (2018) Review: the role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma. Curr Radiopharm 11:14–21
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献